Immutep Limited (ASX:IMM; NASDAQ:IMMP) ("Immutep" or "the Company"), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, is pleased to announce it has received a 2,126,617 euros (~A$3,430,952) research and development (R&D) tax incentive payment in cash from the French Government under its Credit d'Impot Recherche scheme (CIR).
For more information, download the attached PDF.
Download this document